Cutaneous Melanoma - A Review of Systemic Therapies.
Chemotherapy, Adjuvant
Dermatologic Surgical Procedures
/ adverse effects
Disease Progression
Disease-Free Survival
Humans
Immunotherapy
/ adverse effects
Melanoma
/ mortality
Molecular Targeted Therapy
/ adverse effects
Neoadjuvant Therapy
/ adverse effects
Neoplasm Recurrence, Local
Neoplasm Staging
Risk Assessment
Risk Factors
Skin Neoplasms
/ mortality
immunotherapy
systemic therapy
targeted therapy
melanoma
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
03 Jun 2020
03 Jun 2020
Historique:
pubmed:
30
4
2020
medline:
7
4
2021
entrez:
30
4
2020
Statut:
ppublish
Résumé
This decade has brought significantly improved outcomes for patients with advanced melanoma with immunotherapies and targeted treatments offering utility in a variety of settings. In 2020, we can hope for durable long-term responses, and complete remission in a subset of patients with metastatic disease. In the adjuvant setting, approximately 50% improvements in recurrence-free survival are seen both with targeted and immunotherapies. Early data from neoadjuvant immunotherapy clinical trials are very promising. However, responses to treatment are heterogeneous and not always durable; further advances are required, and several emerging strategies are of particular interest. We review the systemic treatment of melanoma, discussing the treatment of unresectable stage III-IV and recurrent disease, outlining curative treatment of cutaneous melanoma in the adjuvant setting and briefly discussing neoadjuvant systemic therapies for advanced melanoma.
Identifiants
pubmed: 32346745
doi: 10.2340/00015555-3496
pmc: PMC9189748
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00141Références
Nat Med. 2019 Jun;25(6):941-946
pubmed: 31171878
Oncoimmunology. 2018 Jul 23;7(9):e1468955
pubmed: 30228935
J Endocr Soc. 2018 Sep 03;3(3):544-559
pubmed: 30788456
J Clin Oncol. 2013 Feb 1;31(4):482-9
pubmed: 23248257
J Clin Oncol. 2012 Jul 10;30(20):2522-9
pubmed: 22614978
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
Clin Cancer Res. 2017 Sep 15;23(18):5339-5348
pubmed: 28611198
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Eur J Cancer. 2019 Mar;109:61-69
pubmed: 30690294
J Immunother Cancer. 2018 Oct 23;6(1):112
pubmed: 30352626
JAMA Oncol. 2019 Feb 1;5(2):187-194
pubmed: 30422243
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Lancet Oncol. 2018 Feb;19(2):181-193
pubmed: 29361468
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
Cell. 2013 Jan 31;152(3):387-9
pubmed: 23374335
N Engl J Med. 2013 Apr 4;368(14):1365-6
pubmed: 23550685
J Clin Oncol. 2013 Feb 10;31(5):616-22
pubmed: 23295794
Cancer J. 2012 Mar-Apr;18(2):176-84
pubmed: 22453019
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
J Immunol. 2003 Dec 1;171(11):6251-9
pubmed: 14634142
BMC Cancer. 2014 Jan 10;14:13
pubmed: 24410877
Eur J Cancer. 2020 May;130:126-138
pubmed: 32179447
Lancet Oncol. 2019 Sep;20(9):1239-1251
pubmed: 31345627
Semin Oncol. 2010 Oct;37(5):533-46
pubmed: 21074069
Sci Transl Med. 2015 Mar 18;7(279):279ra41
pubmed: 25787767
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
Acta Oncol. 2016;55(1):122-3
pubmed: 25811650
Eur J Cancer. 2019 Sep;119:1-10
pubmed: 31400634
Nat Rev Clin Oncol. 2013 Oct;10(10):588-98
pubmed: 23982524
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
J Clin Oncol. 2018 Feb 1;36(4):383-390
pubmed: 28671856
Semin Oncol. 2017 Apr;44(2):136-140
pubmed: 28923212
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
Curr Opin Oncol. 2018 Mar;30(2):125-133
pubmed: 29356698
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Lancet Oncol. 2019 Jul;20(7):961-971
pubmed: 31171444
Ann Oncol. 2017 Jul 01;28(7):1631-1639
pubmed: 28475671
Melanoma Res. 2016 Feb;26(1):83-7
pubmed: 26731560
Lancet Oncol. 2018 Apr;19(4):510-520
pubmed: 29477665
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
Oncoimmunology. 2016 Oct 14;5(12):e1238557
pubmed: 28123875
Oncologist. 2010;15(7):765-71
pubmed: 20538743
J Surg Oncol. 2017 Dec;116(7):856-861
pubmed: 28650570
J Immunother Cancer. 2019 Jun 6;7(1):145
pubmed: 31171039
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
J Surg Oncol. 1999 Aug;71(4):209-13
pubmed: 10440757
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Eur J Cancer. 2020 Feb;126:33-44
pubmed: 31901705
Cancer Cell. 2013 Jul 8;24(1):1-2
pubmed: 23845435
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Eur J Cancer. 2017 Nov;86:37-45
pubmed: 28961465
Cancer Immunol Res. 2014 Apr;2(4):351-60
pubmed: 24764582
Semin Oncol. 2010 Oct;37(5):430-9
pubmed: 21074057
N Engl J Med. 2005 Nov 17;353(20):2135-47
pubmed: 16291983
Ann Oncol. 2017 Oct 01;28(10):2581-2587
pubmed: 28961848
Clin Cancer Res. 2012 Jun 15;18(12):3242-9
pubmed: 22535154
N Engl J Med. 2012 Jan 19;366(3):207-15
pubmed: 22256804
Semin Oncol. 2010 Oct;37(5):440-9
pubmed: 21074058
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
N Engl J Med. 2014 Nov 13;371(20):1867-76
pubmed: 25265494
Immunotherapy. 2019 Jun;11(8):705-723
pubmed: 31045464
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Ther Adv Med Oncol. 2016 Jan;8(1):48-56
pubmed: 26753005
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
pubmed: 23307859
J Transl Med. 2018 Jul 4;16(1):184
pubmed: 29973204